On October 22, the US Treasury proposed adding biotechnology to the list of Chinese sectors that American capital may no longer finance. A week earlier, China's Ministry of Commerce had proposed barring the foreign sale of five biomedical technologies, including cell and gene therapy platforms.
The two moves came in succession, with the US proposal following China's by about a week. The US proposal concerns financing by American capital in Chinese biotechnology; the Chinese proposal concerns foreign sales of five listed biomedical technologies.